No M&A or licensing deal among CMPS, ATAI, NUMI, or MMED is announced before mid-November; sector stays catalyst-starved.

Predicted 2026-09-04 · Resolves 2026-11-15 · corporate · USA

70%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

Four publicly traded psychedelic companies — CMPS (Compass Pathways), ATAI Life Sciences, NUMI (Numinus Wellness), and MMED (MindMed) — will not announce any major merger, acquisition, or licensing deal before November 15, 2026. Large pharmaceutical companies are still waiting for more definitive trial results before committing money. The sector is in a quiet period with few major catalysts on the horizon.

Resolution rule: YES if, by 2026-11-15, none of CMPS, ATAI, NUMI, or MMED announces a definitive M&A transaction or out/in-licensing deal. Sources checked: each company's IR/press-release page and SEC/SEDAR filings. NO if any such named deal is announced before the check date. Check date 2026-11-15.

Nothing in today's signals suggests deal proximity. Big pharma waits for pivotal de-risking. Psych Congress generates talk, not term sheets.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →